Category: Pharma News

Oxford Nanopore and Cyclomics start testing a non-invasive technique for the rapid and precise detection of compounds linked to cancer.

Netherlands startup and Oxford Nanopore Technologies The world’s first nanopore sequencing-based technology for ultra-sensitive detection of circulating tumour DNA has been made available to developers by Cyclomics (ctDNA). The procedure finds and evaluates cell-free DNA (cfDNA) in the blood. As…

Phase-II of the ATH434 trial for multiple system atrophy patient dosing has started, according to Alterity Therapeutics.

The first participant in Alterity Therapeutics’ phase 2 clinical trial of ATH434 in multiple system atrophy (MSA), a rare and severely handicapping Parkinson’s disease, has been dosed in the US, according to the biotechnology company’s announcement. Alterity Therapeutics is dedicated…

In a phase 2a research using Lenvima and fostrox to treat hepatocellular cancer, Medivir has started treating patients.

The first patient with hepatocellular carcinoma (HCC) has begun treatment in phase 2a with the candidate drug fostroxacitabine bralpamide (fostrox) in combination with Lenvima, according to Medivir AB, a pharmaceutical company dedicated to creating novel cancer treatments in regions with…

Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg

BRIDGEWATER, N.J.–(BUSINESS WIRE)– Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for naloxone hydrochloride nasal spray, USP, 4mg, which is the generic version of Narcan® and…

Occlutech starts patient dosing in the FROST study to look into using an atrial flow regulator to treat heart failure with preserved ejection fraction (HFpEF).

One of the top manufacturers of minimally invasive structural heart disease devices, Occlutech Holding AG (Occlutech), has announced the enrollment of the first patient in the FROST-HF study. In the FROST-HF study, patients with heart failure with either preserved ejection…

Back to top
WhatsApp Join Telegram